| Bid price | 3.90 | Open price | 0.00 |
|---|---|---|---|
| Ask price | 4.25 | Prev close | 4.08 |
| High price | 0.00 | Spread | 0.00% |
| Low price | 0.00 | Volume | 0 |
Register now for FREE live Alizyme share prices, Alizyme stock quotes, charts, trades and FREE Alizyme company fundamentals, market news and much much more. Why not upgrade to a premium service and get Alizyme Level 2 Data, indepth research tools and investor commentary for Alizyme (AZM) and other London Stock Exchange equities.
Register now for FREE Alizyme share price charts
| Name | Alizyme | Epic | AZM |
|---|---|---|---|
| Activites | Reuters | AZM.L | |
| ISIN | GB0000374289 | Google Finance | LON:AZM |
| Share Price (p) | 0.00 | Prev. Share Price (p) | 4.08 |
|---|---|---|---|
| Shares in Issue (m) | 0 | Market Cap (£m) | 0 |
| PE Ratio (x) | 0.00 | Div per share (p) | 0.00 |
| Div yield (%) | 0.00 | Div cover (x) | 0.00 |
| EPS (p) | 0.00 | PEG | 0.00 |
Register now for FREE Alizyme company fundamentals
Header updated on 24th April 2008 Market has been looking for an announcement re a licensing deal for Cetilistat, the obesity drug; instead it has been hit with the withdrawal of Renzapride, colonitis drug, following an unauspicious performance at Phase III. Folloiwng has been edited to...
Sunday Telegraph 30 May 2004 Obesity is big news and pharmaceutical companies are intent on profiting from it, says Sylvia Pfeifer If the headlines are to be believed, Britain is fast turning into a nation of overweight binge drinkers slumped in front of the television for whom exercise is...
I read couple of heading this weekend, they suggest to take the profit from AZM(170p). I don`t fully agree with it. I think it is worth to hold longer and they still have space to rise more. Anyone have any suggestion?
Register now for FREE Alizyme share price discussions